EBViously

EBViously is a German biotechnology company spun off from Helmholtz Munich, dedicated to developing a first-in-class vaccine against the Epstein-Barr Virus (EBV). Utilizing a proprietary virus-like particle (VLP) platform, the company aims to prevent infectious mononucleosis and long-term EBV-associated complications such as multiple sclerosis and various cancers. Their lead candidate, EBV-001, is designed to mimic the structure of the virus without containing infectious genetic material, potentially offering a high safety profile and broad immune response. The company is currently advancing its lead program toward clinical trials to address a significant unmet medical need, as no EBV vaccine is currently approved.